Skip To Main Content
IR Advisor on Muck Rack

IR Advisor

As seen in: ADVFN
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile
Back to IR Advisor’s profile

Articles by IR Advisor

Shield Therapeutics PLC Appointment of new Chief Financial Officer (9952Y)

|
By IR Advisor
| ADVFN
Register for streaming realtime charts, analysis tools, and prices.
Open in Who Shared View Duplicates (2) Issue with article?

Shield Therapeutics PLC Q3 2023 U.S. Commercial Highlights (9272V)

|
By IR Advisor
| ADVFN
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Open in Who Shared View Duplicates (2) Issue with article?

Shield Therapeutics PLC PDMR Transaction Notification (8171U)

|
By IR Advisor
| ADVFN
Register for real-time alerts, custom portfolio, and market movers Share Name Share Symbol Market Type Share ISIN Share Description Shield Therapeutics Plc LSE:STX London Ordinary Share GB00BYV81293 ORD 1.5P Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade -0.10 -1.69% 5.80 5.70 5.90 5.90 5.80 5.90 2,077,814 15:56:04 Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap Pharmaceutical Preparations 4.47M -40.44M -0.0522...
Open in Who Shared View Duplicates (3) Issue with article?

Warehouse REIT PLC Investment Advisor share purchase (6638U)

|
By Peter Greenslade, IR Advisor, Richard Gotla
| ADVFN
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Open in Who Shared View Duplicates (2) Issue with article?

Shield Therapeutics PLC Abstract to be presented at Healthcare Conference

|
By IR Advisor
| ADVFN
TIDMSTX Shield Therapeutics PLC 20 October 2023 Shield Therapeutics plc ("Shield" or the "Company" or the "Group") Shield to Present Abstract at 26th Annual Women's Healthcare Conference 2023 on Accrufer(R) London, UK - 20 October 2023: Shield Therapeutics plc (LSE: STX), a commercial stage pharmaceutical company that delivers Accrufer(R)/Feraccru(R) (ferric maltol), an innovative and differentiated specialty pharmaceutical product, to address a significant unmet need for patients suffering...
Open in Who Shared View Duplicates (2) Issue with article?

Shield Therapeutics PLC Chief Financial Officer Transition (8483P)

|
By IR Advisor
| ADVFN
Shield Therapeutics (LSE:STX) Intraday Stock Chart Thursday 12 October 2023 TIDMSTX RNS Number : 8483P Shield Therapeutics PLC 12 October 2023 Shield Therapeutics plc ("Shield" or the "Company" or the "Group") Chief Financial Officer Transition London, UK, 12 October 2023: Shield Therapeutics plc (LSE: STX), a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with its lead product Accrufer(R)/ Feraccru(R) (ferric maltol), announces that Hans-Peter Rudolf is...
Open in Who Shared View Duplicates (2) Issue with article?

Shield Therapeutics PLC Interim results update and business update (9177N)

|
By IR Advisor, unallocated Feraccru
| ADVFN
Shield Therapeutics (LSE:STX) Intraday Stock Chart Thursday 28 September 2023 TIDMSTX RNS Number : 9177N Shield Therapeutics PLC 28 September 2023 Shield Therapeutics plc ("Shield" or the "Company" or the "Group") Interim results update and business update Shield reports strong H1 2023 prescription growth momentum for Accrufer(R) Accelerating prescription growth, with expectations for 80% increase in Q3 2023 KPI performance and new market access expansion puts Shield on track to grow 2023...
Open in Who Shared View Duplicates (2) Issue with article?

Shield Therapeutics PLC Business Update and U.S. Q2 2023 Highlights

|
By - Increase, IR Advisor
| ADVFN
Shield Therapeutics (LSE:STX) Intraday Stock Chart Thursday 20 July 2023 TIDMSTX RNS Number : 5804G Shield Therapeutics PLC 20 July 2023 Shield Therapeutics plc ("Shield" or the "Company" or the "Group") Business Update and U.S. Q2 2023 Highlights Strong Q2 2023 with U.S. Accrufer(R) Prescription Growth Total U.S. prescriptions increased by 50% in 2(nd) quarter to 15,800, including 30% growth in June Completion of commercial expansion to 100 sales representatives, refreshed brand positioning...
Open in Who Shared View Duplicates (2) Issue with article?

Shield Therapeutics PLC Results of 2023 Annual General Meeting

|
By IR Advisor
| ADVFN
Shield Therapeutics (LSE:STX) Intraday Stock Chart Wednesday 28 June 2023 TIDMSTX RNS Number : 2911E Shield Therapeutics PLC 28 June 2023 Shield Therapeutics plc ("Shield" or the "Company" or the "Group") Results of 2023 Annual General Meeting London, UK, 28 June 2023: Shield Therapeutics plc (LSE: STX), a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with its lead product Accrufer(R)/ Feraccru(R) (ferric maltol), announces the results of the voting for...
Open in Who Shared View Duplicates (2) Issue with article?

Shield Therapeutics PLC Grant of share options to the CEO

|
By IR Advisor
| ADVFN
Shield Therapeutics (LSE:STX) Intraday Stock Chart Tuesday 6 June 2023 TIDMSTX RNS Number : 8095B Shield Therapeutics PLC 06 June 2023 Shield Therapeutics plc ("Shield" or the "Company" or the "Group") Grant of share options to the Chief Executive Officer London, UK, 06 June 2023: Shield Therapeutics plc (LSE: STX), a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with its lead product Accrufer(R)/ Feraccru(R) (ferric maltol), announces that on 02 June...
Open in Who Shared View Duplicates (3) Issue with article?

Shield Therapeutics PLC 2022 Annual Report and 2023 AGM Notice

|
By IR Advisor
| ADVFN
Shield Therapeutics (LSE:STX) Intraday Stock Chart Friday 19 May 2023 TIDMSTX RNS Number : 7802Z Shield Therapeutics PLC 19 May 2023 Shield Therapeutics plc ("Shield" or the "Company" or the "Group") 2022 Annual Report and 2023 AGM Notice London, UK, 19 May 2023: Shield Therapeutics plc (LSE: STX), a commercial stage pharmaceutical company focused on the commercialisation of its innovative oral iron therapy for iron deficiency, Accrufer(R)/Feraccru(R) (ferric maltol), announces that the...
Open in Who Shared Issue with article?

Shield Therapeutics PLC Rule 2.9 Announcement and TVR Update

|
By IR Advisor
| ADVFN
Shield Therapeutics (LSE:STX) Intraday Stock Chart Tuesday 9 May 2023 TIDMSTX RNS Number : 8390Y Shield Therapeutics PLC 09 May 2023 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION FOR IMMEDIATE RELEASE Shield Therapeutics PLC ("Shield" or the "Company") Rule 2.9 Announcement and Total Voting Rights Update Following admission to trading on AIM...
Open in Who Shared View Duplicates (3) Issue with article?

Shield Therapeutics PLC Business Update and Unaudited Results

|
By - Cash, IR Advisor
| ADVFN
Shield Therapeutics (LSE:STX) Intraday Stock Chart Thursday 27 April 2023 TIDMSTX RNS Number : 6120X Shield Therapeutics PLC 27 April 2023 Shield Therapeutics plc ("Shield" or the "Company" or the "Group") Business Update and Unaudited Results Total U.S. Accrufer (R) prescriptions increased to more than 25,000 in 2022 & 12% sequential rise in Q1 2023 over Q4 2022 Strong progress made on implementation of collaborative U.S. Sales Agreement with Viatris for Accrufer(R) Funded to support...
Open in Who Shared View Duplicates (2) Issue with article?

Shield Therapeutics PLC Appointment of Chief Commercial Officer

|
By IR Advisor
| ADVFN
Shield Therapeutics (LSE:STX) Intraday Stock Chart Wednesday 5 April 2023 TIDMSTX RNS Number : 3892V Shield Therapeutics PLC 05 April 2023 Shield Therapeutics plc ("Shield" or the "Company" or the "Group") Appointment of Chief Commercial Officer Update on US salesforce expansion - Proven commercial leader with a proven track record of delivering successful product launches - Will oversee all US commercial operations with focus on Accrufer(R) adoption and expansion - Recruitment of expanded...
Open in Who Shared View Duplicates (2) Issue with article?
Show More